RxDoctor Payments Data

Mei Zhang, MD

Family Medicine · Missouri City, TXNPI 1881690246

Payments from drug & device makers

$3,263in general payments, 2019–2025

Across 70 payments — averaging $46.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amarin Pharma, Inc.$366
  • Amgen$339
  • Novo Nordisk$257
  • Gilead$165
  • Sanofi-aventis U.S. LLC$150
  • plus $817 from 12 others

What the payments were for

  • Speaking & faculty fees$1505%
  • Food & beverage$3,07394%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,263 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$172,407
Medicare patients
200
Services billed
1,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl91$86,357
JardianceEmpagliflozin48$69,079
FarxigaDapagliflozin Propanediol51$65,185
ZenpepLipase/Protease/Amylase15$46,123
OzempicSemaglutide35$42,157
Xigduo XrDapaglifloz Propaned/Metformin17$24,894
ProliaDenosumab12$21,071
Icosapent Ethyl20$8,343
Rosuvastatin Calcium302$5,641
Atorvastatin Calcium427$3,924
Metoprolol Succinate206$2,631
Losartan Potassium342$2,489
Telmisartan66$2,421
Humalog Kwikpen U-100Insulin Lispro13$2,363
Omega-3 Acid Ethyl Esters16$1,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$85$69,07948 claims
AstraZenecaFarxiga$1,168$65,18551 claims
Novo NordiskOzempic$257$42,15735 claims
AmgenProlia$339$21,07112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Missouri City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →